We scan new podcasts and send you the top 5 insights daily.
Traditional pharma review processes implicitly depend on knowing a human author's personal habits, such as overclaiming when excited or becoming vague in regulatory sections. Generated AI text erases these fingerprints. It delivers genuine citations and fabricated claims with identical tone, fluency, and authority. Reviewers lose the intuitive mental map of where weak evidence lies, forcing an unnatural shift from noticing obvious tells to actively hunting invisible omissions.
Effective AI detection frames the problem as large-scale authorship identification. By training on paired examples of human versus LLM-generated text on the same prompts, detection models learn to recognize the unique statistical "smell" or stylistic signature of each major AI model.
As AI models advance and establish cleaner track records, human verification drops due to automation bias. A system that fails half as often, reviewed half as carefully, leaves biopharma companies in a worse position because remaining failures are subtler and masked by fluent prose. The apparent success of an AI pilot naturally lowers reviewer vigilance, allowing high-risk errors to circulate undetected.
AI enables rapid book creation by generating chapters and citing sources. This creates a new problem: authors can produce works on complex topics without ever reading the source material or developing deep understanding. This "AI slop" presents a veneer of expertise that lacks the genuine, ingested knowledge of its human creator.
The problem with AI-generated content isn't just generic phrasing but the erosion of reader trust and believability. An effective workflow involves a human writing the initial draft to embed genuine ideas and voice, then using AI tools specifically to strip out repetitive patterns and clean up the text.
Heuristics for spotting AI writing, like the overuse of em dashes, are becoming obsolete as models learn from human feedback. For instance, ChatGPT now uses em dashes *less* frequently than human writers at The Economist, flipping the old tell on its head and complicating detection efforts.
AI-generated content, like product reviews, appears high-quality individually but reveals its artificiality in bulk. It defaults to a safe, descriptive "center of the distribution" (mode collapse), lacking the variation and personality of genuine human writing, making it detectable at scale.
Distortion errors frequently disguise themselves as crisp, competent editing. When summarizing clinical documentation, an AI may compress a narrow demographic into a broad indication, expanding the patient population without explicitly stating a falsehood. Similarly, hedged statements like 'suggested' silently become 'evidence shows'. Because the resulting text is punchier and reads better, human reviewers routinely mistake substantive clinical overstatements for standard summarization.
In the age of AI, 'slop' is not defined by typos or poor formatting, but by well-structured content that lacks a person's unique insight, critical thinking, and accountability. It's the absence of a real, defensible human author behind the words, a problem reviewers can now easily spot.
Historically, well-structured, grammatically correct writing served as a reliable heuristic for an intelligent and serious author. AI completely breaks this connection by allowing anyone to generate perfectly polished prose for any idea, no matter how absurd, removing a key filter for evaluating content.
When reviewers are conditioned to expect AI flaws, tests show that many invent non-existent errors in perfectly clean text. Over-scrutinizing creates massive business friction, slowing output without increasing safety. Rather than tripling the verification load across every draft, review rigor must be systematically calibrated according to the regulatory and clinical consequences of the document rather than a reviewer's subjective feelings of uncertainty.